PCN108 IMPACT OF NEW DRUGS AND BIOLOGICALS ON TREATMENT AND COSTS FOR COLORECTAL CANCER  by Shah, ND et al.
A56 Abstracts
Women who were q40 years of age on January 1st and a64 years of age on December 
31st of each year were extracted. Recipients with a diagnosis of breast cancer or
abnormal breast ﬁ ndings were excluded from the analyses using appropriate ICD-9
codes (174.XX, 233.0X, 238.3X, 239.3X). Data for women with claims for screening
mammography at any time during each calendar year were extracted using following 
CPT code: 76092. Results were reported by age group (40–49 years, 50–59 years, and 
60–64 years), race (White, Black, and others), county of residence, and geographic
area (metro, non-metro urban, non-metro rural) for each calendar year. RESULTS:
There was an estimated 12% increase in the screening mammography between 2000 
and 2005. A consistent increase in the mammography screening was observed during
study period (2000–2005) among women who were 50–59 years of age as compared 
to those between 40–49 and 60–64 years of age. Approximately 90% women who 
underwent screening mammography resided in either metro or non-metro urban areas.
CONCLUSIONS: Screening mammography trends differed among women based on 
demographic characteristics. Further research is needed to evaluate accessibility and 
knowledge among indigent women in order to develop effective breast cancer preven-
tion strategies.
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OBJECTIVES: The aim of this study was to identify health workers’ labor environ-
ment satisfaction in several oncology services from a tertiary referral center and two
second level-hospitals at the Social Security Mexican Institute (IMSS). METHODS: A
cross-sectional and descriptive study was performed within the IMSS in Guadalajara
City, Mexico. The health workers were interviewed using the work environment scale
(WES), this questionnaire contents 90 items through dichotomy answers (true/false)
to evaluate medical staff satisfaction among several item: involvement, cohesion, 
support, autonomy, organization, work-pressure, clarity, control, innovation, guidance 
and comfort. All workers interviewed attend mainly oncology patients. Internal con-
sistency was evaluated through Cronbach’s alpha and ANOVA to obtain statistical 
differences between health workers responses. This questionnaire was previously vali-
dated in Mexico. RESULTS: Eighteen physicians, 27 nurses, 7 medical assistants and
8 radiotherapy technicians were interviewed. The mean response for all health workers 
interviewed satisfaction level including all items was of 49% (23% to 78%), the lowest 
satisfaction level was for the comfort item (39%) and the highest was for the clarity 
item (59%). We did not ﬁ nd differences between medical staff specialties, with excep-
tion of nurses, whom were the lowest satisfaction level group (38%; p  0.001). 
However, statistical differences among all the hospitals studied in the assessment were
found. In the tertiary referral center physicians showed the lowest work environment
satisfaction in the cohesion item (40%; p  0.09) followed by nurses giving services 
to inpatients (38%; p  0.01). In second-level patients the lowest work environment 
satisfaction level was obtained in medical assistants in clarity items (37%; p  0.03)
and guidance (39%; p  0.08). CONCLUSIONS: Using the WES scale in three 
Mexican hospitals, the analysis showed that medical staff that attend oncology 
patients, are dissatisﬁ ed with their work environment. The less satisﬁ ed were nurses 
and medical assistants.
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OBJECTIVES: To understand Canadian and U.S. health system compliance with
cancer screening guideline information with respect to the age of screening initiation.
METHODS: Canadian and U.S. cancer screening generally identify ages when cancer
screening should be initiated. We use a regression discontinuity research design to
identify discrete increases in Canadian and U.S. cancer screenings in the past two 
years at the guideline recommended ages. Multivariate logistic regression analyses 
were performed using breast, prostate and colorectal cancer screening within the 
past two years as the dependent variables of interest. Logistic regression models also 
adjust for respondent demographic and socioeconomic characteristics. We analyze 
screening for adult individuals from the 2006 Behavioral Risk Factor Social Survey, 
2003 National Health Interview and 2003 and 2005 Canadian Community Health 
Surveys. RESULTS: Graphical and logistic regression analyses identiﬁ ed large statisti-
cally signiﬁ cant increases in cancer screening rates precisely at the U.S. guideline rec-
ommended screening initiation ages. U.S. breast, colorectal and prostate screenings
increase by 33%, 33% and 25% precisely at the guideline recommended ages(age 
40 for breast and age 50 for colorectal and prostate cancers). Similarly in Canada 
we found a 20% increase in breast cancer screening at age 50, the Canadian guideline 
recommended age for screening initiation. We did not ﬁ nd a discrete increase in the
Canadian colorectal cancer screening rate at the Canadian recommended screening
age of 50. CONCLUSIONS: U.S. and Canadian cancer screening utilization is gener-
ally consistent with each country’s guideline recommendations regarding age. The 
cross-country differences in screening identiﬁ ed in this study can potentially explain
cross-country differences in cancer mortality rates and affect interpretation of cross-
country cancer statistics. The similarity of other OECD cancer screening guidelines
to Canadian screening guidelines suggests that results from this study have broader 
applicability to comparisons of cancer statistics between U.S. and other OECD 
countries.
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OBJECTIVES: To understand the impact of U.S. cancer screening guideline informa-
tion on U.S. cancer screening and cancer detection. METHODS: We use an instru-
mental variables research design to identify the effects of breast, colorectal and
prostate cancer screening guideline information on cancer detection. U.S. guidelines
specify an age at which screening should begin, implicitly recommending that screen-
ing not occur for asymptomatic individuals below that age. We ﬁ rst estimate compli-
ance with guideline information from the difference in age-speciﬁ c screening rates just
below and above the ages at which clinical guidelines recommend that screening begin.
We then perform instrumental variables regression analyses to estimate the effect of 
guideline induced screening on cancer detection. U.S. cancer screening and incidence 
data (years 2000–2005) are derived from the Behavioral Risk Factor Social Survey,
the National Health Interview Survey and the SEER Program. RESULTS: Age-speciﬁ c 
screening rates from national BRFSS and NHIS survey data indicate that U.S. breast, 
colorectal and prostate cancer screening in the last year rise by 55%, 88% and 29% 
precisely at the guideline recommended ages(age 40 for breast cancer and age 50 for 
colorectal and prostate cancers). Results from instrumental variables analyses indicate
that a 1% point increase in screening at the guideline recommended ages leads to an 
additional case of breast and colorectal cancer detected per 100,000 individuals. The
substantial increase in prostate cancer screening did not have an identiﬁ able effect on 
prostate cancer detection. CONCLUSIONS: We used an instrumental variables strat-
egy to identify the impact of guideline information on cancer screening and detection. 
Guideline information induces substantial increases in breast, colorectal and prostate 
cancer screening but these changes only lead to increases in breast and colorectal
cancer detection. These results suggest that reductions in the use of the PSA test will 
result in substantial cost savings with minimal reductions in health.
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OBJECTIVES: There have been a number of new drugs and biologicals approved by
the FDA in the last ﬁ ve-years for the treatment of colorectal cancer (CRC). Objective 
of this study was to compare the initial treatments and overall medical costs for 
working-age persons with CRC before and after the introduction of these treatments.
METHODS: This retrospective cohort study was based on a large administrative
database and included patients with an ICD-9 diagnosis of CRC. We looked at indi-
viduals treated for CRC in the period prior to introduction of new chemotherapy and
biological agents (January 2002–December 2002) and the period after the introduction 
of two biologicals (bevacizumab and cetuximab) and one chemotherapy agent (oxali-
platin), (June 2004–May 2005). We assigned patients to stage of diagnosis based on 
treatment regimens. We identiﬁ ed 2545 patients (61% Stage III) with CRC in the 
pre-period and 4413 patients (59% Stage III) with CRC in the post-period. We esti-
mated mean total medical costs in the pre- and post- periods using the Kaplan-Meier 
sample average estimator. RESULTS: The predominant treatment regimen in the
pre-period for stage III CRC was 5-FU/Leucovorin (77%), while the pre-dominant
regimens the post-period were 5-FU/Leucovorin (36%) and FOLFOX (35%). The 
pre-dominant treatment regimen for stage IV CRC was IFL/FOLFIRI (50%), while 
the most common regiments in the post-period were IFL/FOLFIRI (22%) and
FOLFOX (23%). Additionally, over 14% of the patients received a biological agent 
in the post-period. There was also a signiﬁ cant increase in total medical costs over 
this time period. The mean costs for Stage III and Stage IV CRC patients increased 
from $56,187 in the pre-period to $101,049 in the post-period (p  0.001). CONCLU-
SIONS: The introduction of new treatments for CRC signiﬁ cantly changed the treat-
ment patterns for both Stage III and Stage IV CRC. These changes in treatment were 
accompanied by a signiﬁ cant increase total medical costs.
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OBJECTIVES: The occurrence of breast cancer causes signiﬁ cant morbidity and
mortality among patients and results in considerable economic impact on patients, 
health care payers, and society. The purpose of this study is to determine the trends
in the prevalence of breast cancer and associated health care utilization and costs
among an indigent population covered by a state Medicaid program. METHODS:
Retrospective analysis of a state Medicaid fee-for-service administrative claims dataset 
